Risk-based treatment strategy in ELEVATEd blood pressure (ELEVATE): a pragmatic randomized clinical trial.

ELEVATE will evaluate the effectiveness in terms of reducing vascular organ damage (arterial stiffness) and CVD events of a risk-based treatment strategy for individuals with elevated BP (BP 130-139/80-89 mmHg), compared to standard care. This will be a randomised, parallel, open-label, pragmatic, investigator-initiated, interventional clinical trial that will include patients with elevated BP along with the presence of a high-risk condition.
Additionally, the trial will evaluate office and home BP, drug-related serious adverse effects, patient-reported outcomes such as quality of life, adherence and treatment satisfaction, cost-effectiveness. Long-term effectiveness and safety outcomes.